3LenaertsAJ,Gruppo V,Marietta KS,et al. Preclinical testing of the nitroimidazopyran PA-284 for activity againstM ycobacterium tuberculosis in a series of in vitro and in vivo models[J].1 Antimicrob Agents Chemother,2005,49 (6):22941.
4Tyagi S,Nuermberger E,Yoshimatsu T,et al. Bactericidal activity of the nitroimidazopyran PA-284 in a murine model of tuberculosis[J].1 Antimicrob Agents Chemother,2005,49 (6):22891.
5CynamonMH,Klemens SP,Sharpe CA,et al1 Activities of several novel oxzaolidinones against Mycobacterium tuberculosis in a marine model[J].1 Antimicrob Agents Chemother,1999,43:11891.
二级参考文献18
1Mitchell I,Wendon J,fitt S,et al.Anti-tuberculosis therapy and acute liver failure.Lancet,1995,345(8949):555-556.
2Saigal S,Agarwal SR,Nandecsh HP,et al.Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease:a preliminary report.J Gastroenterol Hepatol,2001,16(9):1028-1032.
3Yew WW,Chau CH,Wong PC,et al.Ciprofloxacin in the managemnt of pulmonary tuberculosis in the face of hepatic dysfunction.Drugs Exp Clin Res,1995,21 (2):79-83.
4Yew WW,Lee J,Wong PC,et al.Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction.Int J Clin Pharmacol Res,1992,1294):173-178.
5Schaberg T,Rebhan K,Lode H.Risk factors for side-effects of isoniazid,rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.Eur Respir J,1996,9(10):2026-2030.
6van den Brande P,van Steenbergen W,Vervoort G,et al.Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.Am J Respir Crit Care Med,1995,152(5 Pt 1):1705-1708.
7Coplebunders R,Lambert ML.Management of co-infection with HIV and TB.BMJ,2002,324(7341 ):802-803.
